VHCP Management III’s KalVista Pharmaceuticals KALV Stock Holding History

VHCP Management III’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$11M	Sell	619,905 -17,979	-3%	-$235K	2.19%	10
2019 Q3	$7.4M	Hold	637,884	–	–	4.57%	9
2019 Q2	$14.1M	Sell	637,884 -332,746	-34%	-$7.8M	6.6%	4
2019 Q1	$27.8M	Sell	970,630 -314,301	-24%	-$6.81M	16.19%	1
2018 Q4	$25.4M	Hold	1,284,931	–	–	18.45%	1
2018 Q3	$28.4M	Buy	+1,284,931	New	+$17.4M	21.47%	1

Other funds holding KALV

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

GTC

Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

VHCP Management III's KALV Position: Q4 2019 in Review

VHCP Management III reduced its KalVista Pharmaceuticals (KALV) stake by 2.8% in Q4 2019, selling an estimated $235K and leaving 619,905 shares worth $11M. The position accounts for 2.19% of the portfolio, ranked #10.

VHCP Management III first reported a position in KALV in Q3 2018 and has held it in 6 quarters since. The position peaked at $28.4M in Q3 2018. 73 funds tracked by Wall St. Rank hold KALV as of Q4 2019.

VHCP Management III held 619,905 shares of KalVista Pharmaceuticals worth $11M as of Q4 2019.
VHCP Management III sold 17,979 KalVista Pharmaceuticals shares in Q4 2019, an estimated $235K.
KalVista Pharmaceuticals made up 2.19% of VHCP Management III's portfolio in Q4 2019, its #10 holding.
VHCP Management III first reported a position in KalVista Pharmaceuticals in Q3 2018 and has held it in 6 quarters since.
VHCP Management III's KalVista Pharmaceuticals position peaked at $28.4M in Q3 2018.
73 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q4 2019.

Based on VHCP Management III's 13F filing for Q4 2019, filed 13 Feb 2020.